Condition: Malignant Germ Cell Tumor · Lung Adenocarcinoma · Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma · Sponsor: Duboce Biopharmaceuticals, Inc.
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.
This description comes directly from the study's public registry record.
Lisa Knapp · +1 (650) 442-3367 · lknapp@tcglsoleil.com
Always discuss trial participation with your own doctor first.
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START New Jersey | East Brunswick, New Jersey, United States | Recruiting |
| START New York | Lake Success, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07705035